Endocyte, which is developing small molecule drug conjugates to treat cancer and inflammatory diseases, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The West Lafayette, IN-based company, which was founded in 1995 and booked $3 million in sales last year, plans to list on the NASDAQ under the symbol ECYT. RBC Capital Markets and Leerink Swann are the lead underwriters on the deal. No pricing terms were disclosed.
